Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Minimal residual disease

R S Negrin1

  • 1Stanford University, Division of Bone Marrow Transplantation, CA 94305, USA.

Current Opinion in Hematology
|November 14, 1998
PubMed
Summary
This summary is machine-generated.

Accurate detection of minimal residual disease (MRD) is crucial for personalized cancer treatment. This review covers advances in MRD detection tools and their ability to predict clinical outcomes for better patient management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.

Bone marrow transplantation·2015
Same author

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation.

Blood cancer journal·2014
Same author

Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma.

Bone marrow transplantation·2011
Same author

Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure.

Bone marrow transplantation·2009
Same author

Visualization of tumor growth and response to NK-T cell based immunotherapy using bioluminescence.

Annals of hematology·2003
Same author

Advancing animal models of neoplasia through in vivo bioluminescence imaging.

European journal of cancer (Oxford, England : 1990)·2002
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Oncology
  • Clinical Diagnostics
  • Biomarker Discovery

Background:

  • Accurate and sensitive detection of minimal residual disease (MRD) is a significant challenge in managing malignant disorders.
  • Current routine radiographic and pathologic studies often lack the necessary sensitivity for effective MRD detection.
  • Effective MRD detection is essential for tailoring treatment strategies, ensuring timely aggressive therapy for some patients while avoiding unnecessary toxicity for others.

Purpose of the Study:

  • To review recent advancements in the development and standardization of sensitive and specific tools for MRD detection.
  • To evaluate studies from the past year that assess the reliability of MRD assays and their predictive value for clinical outcomes.
  • To highlight the importance of MRD detection in guiding individualized treatment decisions for cancer patients.

Related Experiment Videos

Main Methods:

  • Review of recent scientific literature focusing on novel techniques for MRD detection.
  • Analysis of clinical studies published within the last year investigating the correlation between MRD assay results and patient outcomes.
  • Synthesis of information on the standardization of MRD detection methodologies.

Main Results:

  • Recent advances have led to the development of more sensitive and specific tools for detecting minimal residual disease.
  • Emerging evidence suggests that certain MRD assays can reliably predict clinical outcomes, aiding in treatment stratification.
  • The review synthesizes findings on the current state of MRD detection technologies and their clinical utility.

Conclusions:

  • Standardized and validated tools for minimal residual disease detection are critical for personalized cancer therapy.
  • The predictive value of MRD assays for clinical outcomes is increasingly being established, supporting their use in treatment decisions.
  • Further research and validation are necessary to fully integrate advanced MRD detection into routine clinical practice for malignant disorders.